The Protein Analytical group at Jounce Therapeutics is looking for an individual with expertise in antibody and protein therapeutics, especially in the fields of protein characterization/developability assessment. In this role you will oversee a small team within the Protein Analytics group and play a leading role in characterizing and developing drug candidates in pre-clinical and clinical stages. This role will be responsible for managing internal resources across multiple programs and providing strategy through the drug development pipeline. The successful candidate will have strong protein biochemistry and biotherapeutic discovery knowledge, be proficient at designing and executing lab experiments, and have demonstrated the ability to lead and manage a small group of scientists. In this role you will have the opportunity to work cross functionally across multiple departments including discovery/biology, Ab technology, protein production and CMC. You will spend approximately 25% of your time in the lab, both conducting your own experiments and mentoring other scientists. This is an exciting opportunity to play an important role in the discovery and development of novel biotherapeutics for immuno-oncology.
Diversity and Inclusion Statement
Jounce strives to create a workplace that reflects the diversity of cancer patients, and where all feel included and valued because differences. Actively including people who add to our culture and enhance our values leads to better decisions and outcomes for those we serve – patients, all patients. Beyond our walls, our focus is on addressing inequities in opportunities for STEM education, careers opportunities in Biotech, and access to cancer care.
Equal Opportunity Employer
Jounce Therapeutics is an equal opportunity employer and does not discriminate in its employment decisions on the basis of race, color, national origin, age, physical or mental disability, marital status, religion, creed, sex, or political beliefs. We offer a competitive salary and benefits package. All applicants should be legally entitled to work for any employer in the U.S.
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and aiming to provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce’s highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounce’s internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounce’s most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce’s broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. All applicants should be legally entitled to work for any employer in the U.S.